Positron Emission Tomography/Computed Tomography in Thyroid Cancer

Bal, Chandrasekhar; Chakraborty, Debesh; Khan, Dikhra

doi:10.1016/j.cpet.2021.12.004

Cited by 6 publications

(10 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is characterized by rapid growth, extensive local invasion, and very poor survival (6–8 month median survival). PDTC represents an intermediate histologic subtype between DTC and ATC, also with poor prognosis [65]. Both tumors are typically diagnosed with ultrasound or computed tomography, followed by FNA.…”

Section: Poorly Differentiated (Pdtc) and Anaplastic Thyroid Cancer (...mentioning

confidence: 99%

“…Rising thyroglobulin levels typically prompts neck ultrasound to evaluate for structural evidence of recurrent disease, as well as a diagnostic I-131 scan to identify iodine-avid metastases that could be targeted for RAI therapy. However, such iodine scans are frequently negative due to tumor dedifferentiation and down-regulation of the NIS after RAI, conferring 'iodine resistance' [65]. Empiric retreatment of such patients with RAI was not shown to induce substantial tumor response or improve survival [66].…”

Section: Recurrent Iodine-refractory and Noniodine Avid Differentiate...mentioning

confidence: 99%

“…Current ATA guidelines recommend FDG-PET/CT only in patients with elevated Tg >10 ng/mL and negative iodine scan [37] although 10-20% of patients with Tg levels less than this threshold may show evidence of disease [76]. PET findings guide subsequent management: localized FDG-avid metastases may be targeted for surgical resection or external beam radiation (EBRT), whereas more widespread metastases prompt treatment with systemic tyrosine kinase inhibitors, including lenvatinib and sorafenib [65]. Follow-up FDG-PET/CT may then be used to monitor functional tumor response to therapy [78].…”

Section: Recurrent Iodine-refractory and Noniodine Avid Differentiate...mentioning

confidence: 99%

See 2 more Smart Citations

Advanced imaging and theranostics in thyroid cancer

Roseland

Dewaraja

Wong

2022

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of reviewThyroid cancers are endocrine neoplasms with diverse gene expression and behavior, for which constantly evolving anatomic and functional imaging/theranostic agents have an essential role for diagnosis, staging, and treatment. Recent findingsTo achieve definitive diagnosis, neck ultrasound and associated risk stratification systems, notably Thyroid Imaging Reporting and Data System (TI-RADS), allow improved thyroid nodule characterization and management guidance. Radioactive iodine-131 (RAI) has long played a role in management of differentiated thyroid cancer (DTC), with recent literature emphasizing its effectiveness for intermediate-high risk cancers, exploring use of dosimetry for personalized medicine, and potential for retreatment with RAI following tumor redifferentiation. Iodine-124 positron emission tomography/computed tomography (PET/ CT) has promising application for DTC staging and dosimetry. F18-fluorodeoxyglucose (FDG) PET/CT is used for staging of high risk DTC and identification of noniodine-avid disease recurrences, with metabolic uptake consistently portending poor prognosis. Poorly differentiated and anaplastic thyroid cancers are best assessed with anatomic imaging and F18-FDG PET/ CT, though recent studies show a potential theranostic role for Ga68/Lu177-prostate-specific membrane antigen. Medullary thyroid cancers are evaluated with ultrasound, CT, magnetic resonance imaging, and various positron-emitting radiotracers for PET imaging (F18-DOPA, F18-FDG, and recently Ga68-1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid (DOTA)--octreotate (DOTATATE)); the latter may enable treatment with Lu177-DOTATATE. SummaryMultidisciplinary collaboration is essential to streamline appropriate management, given the wide array of available imaging and new therapies for metabolic and genetically complex cancers.

show abstract

Section: Poorly Differentiated (Pdtc) and Anaplastic Thyroid Cancer (...mentioning

confidence: 99%

Section: Recurrent Iodine-refractory and Noniodine Avid Differentiate...mentioning

confidence: 99%

Section: Recurrent Iodine-refractory and Noniodine Avid Differentiate...mentioning

confidence: 99%

See 1 more Smart Citation

Advanced imaging and theranostics in thyroid cancer

Roseland

Dewaraja

Wong

2022

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

show abstract

“…Normal cells are surrounded the cancer cells in the body and these cells resemble each other, so it is challenging to diagnose and cure cancer. A few of the common procedures are used to diagnose cancers include Magnetic Resonance Imaging (MRI) [6,7], Computed Tomography (CT) [8][9][10], Positron Emission Tomography (PET) [9][10][11], flow cytometry [12,13], and biopsy [14][15][16][17][18][19][20]. Liquid biopsy, a non-invasive cancer cell detection method, calls for the collection of bodily fluids with little to no sample preparation [21].…”

Section: Introductionmentioning

confidence: 99%

Advanced electrocatalytic materials based biosensors for cancer cell detection – A review

et al. 2023

View full text Add to dashboard Cite

Herein, we have highlighted the latest developments on biosensors for cancer cell detection. Electrochemical (EC) biosensors offer several advantages such as high sensitivity, selectivity, rapid analysis, portability, low‐cost, etc. Generally, biosensors could be classified into other basic categories such as immunosensors, aptasensors, cytosensors, electrochemiluminescence (ECL), and photo‐electrochemical (PEC) sensors. The significance of the EC biosensors is that they could detect several biomolecules in human body including cholesterol, glucose, lactate, uric acid, DNA, blood ketones, hemoglobin, and others. Recently, various EC biosensors have been developed by using electrocatalytic materials such as silver sulfide (Ag2S), black phosphene (BPene), hexagonal carbon nitrogen tube (HCNT), carbon dots (CDs)/cobalt oxy‐hydroxide (CoOOH), cuprous oxide (Cu2O), polymer dots (PDs), manganese oxide (MnO2), graphene derivatives, and gold nanoparticles (Au‐NPs). In some cases, these newly developed biosensors could be able to detect cancer cells with a limit of detection (LOD) of 1 cell/mL. In addition, many remaining challenges have to be addressed and validated by testing more real samples and confirm that these EC biosensors are more accurate and reliable to measure cancer cells in the blood and salivary samples.

show abstract

“…In recent decades, 18 F-deoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) has been widely used in clinical practice (7), and 18 F-FDG PET-CT imaging has significantly improved the detection rate of thyroid cancer (8). In a previous study, approximately 1/3 of tumors detected by 18 F-FDG PET-CT were thyroid cancer (9).…”

Section: Introductionmentioning

confidence: 99%

The use of positron emission tomography in thyroid cancer: a bibliometric analysis

Zhang¹,

Zhang²,

Liu³

et al. 2022

Gland Surg

View full text Add to dashboard Cite

Background: Thyroid cancer is a common malignant tumor, and its incidence is rising. Positron emission tomography-computed tomography (PET-CT) is of great value in diagnosing and monitoring thyroid cancer. The purpose of this study is to analyze the current research status of the use of PET-CT in thyroid cancer.Methods: We used the Science Citation Index-Expanded (SCI-E) database in the Web of Science Core Collection (WOSCC) as the data source for the literature search. The search was carried out with ("thyroid cancer" OR "thyroid carcinoma") AND "positron emission tomography", and the results were analyzed with the bibliometric R software package. The analysis included the number of documents published in this field by each country, the cooperative relationship between countries, the number of documents published by institutions, the cooperative relationship between institutions, the number of documents published by researchers, the cooperative relationship between researchers, the location of researchers being cited, the number of documents published in journals, and the use of keywords.Results: One thousand and six hundred and seven papers were finally included, and the number of published papers each year showed a trend of fluctuating growth before reaching a peak in 2010, followed by a decreasing trend. The United States published the largest number of documents and was cited far more frequently than other countries. The research institute with the largest number of published articles was the Memorial Sloan Kettering Cancer Center in New York, USA. The cooperation relationship of authors presented a clustered distribution, and the authors in the same cluster often came from the same research institution or country. The professional journal "Thyroid" published the largest amount of studies in this field. According to Bradford's rules, nine core journals in this field were determined. The result of our keyword analysis showed that the most commonly used keyword was "positron emission tomography", followed by "cancer" and "carcinoma". The research in this field focused on follow-up and management of thyroid cancer, especially papillary thyroid cancer. Conclusions:The number of studies in this field shows a decreasing trend, and PET is essential in the follow-up monitoring of thyroid cancer patients.

show abstract

Positron Emission Tomography/Computed Tomography in Thyroid Cancer

Cited by 6 publications

References 95 publications

Advanced imaging and theranostics in thyroid cancer

Advanced imaging and theranostics in thyroid cancer

Advanced electrocatalytic materials based biosensors for cancer cell detection – A review

The use of positron emission tomography in thyroid cancer: a bibliometric analysis

Contact Info

Product

Resources

About